Barclays Cuts Ralliant (NYSE:RAL) Price Target to $52.00

Ralliant (NYSE:RAL) had its target price decreased by Barclays from $60.00 to $52.00 in a research note issued to investors on Monday,Benzinga reports. Barclays currently has an overweight rating on the stock.

RAL has been the topic of a number of other research reports. Morgan Stanley reissued an “overweight” rating and issued a $45.00 price objective on shares of Ralliant in a research note on Friday, February 6th. Citigroup lowered their target price on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Oppenheimer dropped their price target on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating on the stock in a research report on Friday, February 6th. Vertical Research raised shares of Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Friday, February 6th. Finally, Truist Financial lowered their price objective on shares of Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Ralliant presently has a consensus rating of “Hold” and a consensus price target of $50.50.

Ralliant Trading Down 0.6%

Shares of NYSE:RAL opened at $42.78 on Monday. The company has a 50 day moving average of $51.11 and a 200-day moving average of $46.62. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.38. The firm has a market cap of $4.83 billion and a P/E ratio of 21.83. Ralliant has a twelve month low of $37.27 and a twelve month high of $57.02.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The company’s revenue was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 9th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is currently 10.20%.

Insider Buying and Selling at Ralliant

In other news, SVP Amir A. Kazmi bought 2,545 shares of the firm’s stock in a transaction on Friday, February 6th. The stock was bought at an average cost of $39.27 per share, for a total transaction of $99,942.15. Following the completion of the acquisition, the senior vice president directly owned 39,699 shares in the company, valued at $1,558,979.73. This represents a 6.85% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Anelise Angelino Sacks bought 2,000 shares of the company’s stock in a transaction dated Monday, February 9th. The stock was purchased at an average cost of $41.25 per share, for a total transaction of $82,500.00. Following the completion of the transaction, the director owned 5,403 shares of the company’s stock, valued at $222,873.75. This represents a 58.77% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders bought 5,795 shares of company stock valued at $232,405.

Institutional Trading of Ralliant

A number of hedge funds have recently modified their holdings of the business. Nordea Investment Management AB bought a new position in Ralliant in the 2nd quarter worth approximately $29,477,000. Cullen Frost Bankers Inc. bought a new stake in shares of Ralliant in the second quarter valued at approximately $144,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Ralliant in the second quarter worth $1,410,000. JPMorgan Chase & Co. bought a new position in Ralliant during the second quarter worth $18,494,000. Finally, Allspring Global Investments Holdings LLC raised its stake in Ralliant by 5,269.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 317,038 shares of the company’s stock valued at $14,000,000 after purchasing an additional 311,134 shares during the last quarter.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Company insiders (directors and an SVP) bought shares this week, signaling management confidence and providing a support signal for some investors. Insider Buying Alert
• Positive Sentiment: Vertical Research upgraded RAL (reported by media), which can attract buyers and help stabilize demand. Vertical Research Upgrade
• Neutral Sentiment: Ralliant will present at Citi and Barclays investor conferences Feb. 17–18 — management may use these forums to clarify impairment drivers and outlook (could reduce uncertainty if handled well). Investor Conference Notice
• Neutral Sentiment: Some sell‑side firms trimmed price targets (Barclays, Citi, Oppenheimer et al.) — mixed analyst adjustments leave consensus still above current levels but reduce near‑term enthusiasm. Analyst Target Moves
• Negative Sentiment: Ralliant disclosed a $1.4B non‑cash goodwill impairment in its Test & Measurement segment and trimmed FY‑2026 guidance — a material accounting charge that directly pressured the stock and prompted analyst downgrades. Impairment / Guidance Notice
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Kessler Topaz, Kaplan Fox, Kirby McInerney, Bragar Eagel & Squire, etc.) have opened investigations into the timing and disclosure around the impairment and dividend — this raises litigation, regulatory and reputational risk. Levi & Korsinsky Alert
• Negative Sentiment: Short interest jumped ~58.7% in January (~3.75M shares, ~3.3% of float), increasing bearish positioning that can amplify downside and intraday volatility.
• Negative Sentiment: Independent downgrades (e.g., Zacks strong‑sell, Weiss Ratings cut) add selling pressure and can limit buyers until uncertainty eases. Zacks

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.